Literature DB >> 1356014

Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells.

M De Bortoli1, C Dati, S Antoniotti, P Maggiora, M L Sapei.   

Abstract

Expression of the c-erbB-2 (neu, HER-2) oncogene is found to be subjected to hormonal and developmental regulation in normal as well as neoplastic mammary cells. We have previously reported that estrogens inhibit c-erbB-2 expression at both the mRNA and protein level in estrogen receptor (ER)-positive, but not in ER-negative, breast cancer cell lines. Reversion of c-erbB-2 inhibition is seen with tamoxifen. The effect on c-erbB-2 expression of several other hormones and factors, which influence mammary cell growth and differentiation, has been studied. Our observations indicate that, in normal and neoplastic mammary cells, c-erbB-2 expression is inversely related to cell proliferation. While estrogens, anti-estrogens and cAMP clearly regulate c-erbB-2 mRNA levels, epidermal growth factor dramatically decreases the c-erbB-2 protein without affecting the level of c-erbB-2 mRNA. Therefore, different signals converging in terms of cell proliferation regulate c-erbB-2 expression by different molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356014     DOI: 10.1016/0960-0760(92)90183-j

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

1.  Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice.

Authors:  H Naundorf; I Fichtner; G J Saul; W Haensch; B Büttner
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  Arecoline induced disruption of expression and localization of the tight junctional protein ZO-1 is dependent on the HER 2 expression in human endometrial Ishikawa cells.

Authors:  Sarbani Giri; Kevin M Poindexter; Shyam N Sundar; Gary L Firestone
Journal:  BMC Cell Biol       Date:  2010-07-06       Impact factor: 4.241

3.  Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery.

Authors:  Y-M Tsai; H-M Hsu; C-J Chen; K-F Hsu; H-L Fan; H Chang; D-C Chan; J-C Yu
Journal:  Ir J Med Sci       Date:  2013-06-12       Impact factor: 1.568

4.  Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer.

Authors:  Noriko Yoshimura; Nobuhiro Harada; Ida Bukholm; Rolf Kåresen; Anne-Lise Børresen-Dale; Vessela N Kristensen
Journal:  Breast Cancer Res       Date:  2003-12-11       Impact factor: 6.466

5.  Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Authors:  Silvia Darb-Esfahani; Sibylle Loibl; Berit M Müller; Marc Roller; Carsten Denkert; Martina Komor; Karsten Schlüns; Jens Uwe Blohmer; Jan Budczies; Bernd Gerber; Aurelia Noske; Andreas du Bois; Wilko Weichert; Christian Jackisch; Manfred Dietel; Klaus Richter; Manfred Kaufmann; Gunter von Minckwitz
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

6.  Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells.

Authors:  E Dittrich; M Offterdinger; S M Schneider; Ch Dittrich; H Huber
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

7.  Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas.

Authors:  H Naundorf; K Parczyk; W Zschiesche; S Reinecke; B Büttner; G J Saul; B Sinn; I Fichtner
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.322

8.  Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.

Authors:  T Watanabe; T Fukutomi; H Tsuda; I Adachi; T Nanasawa; H Yamamoto; K Abe
Journal:  Jpn J Cancer Res       Date:  1993-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.